Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.67 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | CA5A | P35218 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.58 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.58 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.53 |
| ▸ | ILK | Q13418 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23926457 | 0.86 | RIPK1 (0.53) | SMN1; SMN2ALDH1A1HTTCYP3A4TSHR | |
| SCHEMBL15794568 | 0.83 | SMN1; SMN2 (0.69) | SMN1; SMN2ALDH1A1HTTCYP3A4TSHR | |
| SCHEMBL3932455 | 0.81 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1HTTCYP3A4TSHR | |
| SCHEMBL334808 | 0.81 | ALDH1A1 (1.00) | SMN1; SMN2ALDH1A1HTTCYP3A4TSHR | |
| SCHEMBL3244369 | 0.81 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1HTTCYP3A4TSHR | |
| SCHEMBL1247145 | 0.81 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1HTTCYP3A4TSHR | |
| SCHEMBL146922 | 0.81 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1HTTCYP3A4TSHR | |
| SCHEMBL10667967 | 0.80 | PDK1 (1.00) | SMN1; SMN2ALDH1A1HTTCYP3A4TSHR | |
| Water SCHEMBL27718168 | 0.80 | SMN1; SMN2 (0.65) | SMN1; SMN2ALDH1A1HTTCYP3A4TSHR | |
| SCHEMBL9798029 | 0.80 | DYRK1A (0.65) | SMN1; SMN2ALDH1A1HTTCYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098292-A1 | New Compounds Useful for Treating CNS Disorders | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | US | claimed |
| EP-1765815-A2 | NEW COMPOUNDS USEFUL FOR TREATING CNS DISORDERS | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | claimed |
| WO-2006004507-A2 | NEW BENZOTHIAZOLE DERIVATIVES USEFUL FOR TREATING CNS DISORDERS | ASTRAZENECA AB (SE) | 2006-01-12 | — | — | WO | claimed |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| WO-2025215153-A1 | PRMT5 INHIBITORS | Ryvu Therapeutics S.A. (PL) | 2025-10-16 | — | — | WO | disclosed |
| US-20250101018-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2025-03-27 | — | — | US | disclosed |
| CN-113727972-B | Novel hydrazone derivatives having terminal amine groups substituted with aryl or heteroaryl groups and use thereof | 韩国科学技术研究院 | 2024-12-27 | — | — | CN | disclosed |
| US-12116364-B2 | Heteroaryl compounds and uses thereof | APRINOIA THERAPEUTICS INC. (CN) | 2024-10-15 | — | — | US | disclosed |
| US-20230374006-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230374006-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230374006-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2023-11-23 | — | — | US | disclosed |
| EP-1828177-B1 | NOVEL MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1828177-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007086800-A1 | NOVEL HETEROARYL SUBSTITUTED BENZOTHIAZOLES | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
| EP-1797054-A2 | ARYL-AMINO SUBSTITUTED PYRROLOPYRIMIDINE MULTI-KINASE INHIBITING COMPOUNDS | OSI Pharmaceuticals, Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| EP-1765815-A2 | NEW COMPOUNDS USEFUL FOR TREATING CNS DISORDERS | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | disclosed |
| US-20060211678-A1 | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006066173-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006017443-A2 | ARYL-AMINO SUBSTITUTED PYRROLOPYRIMIDINE MULTI-KINASE INHIBITING COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| WO-2006004507-A2 | NEW BENZOTHIAZOLE DERIVATIVES USEFUL FOR TREATING CNS DISORDERS | ASTRAZENECA AB (SE) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374006-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | MAPT, APP, SLCO1B3 | SMN1; SMN2 2412/4885ALDH1A1 1918/4885HTT 10/4885 |
| US-20060211678-A1 | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | BMX, ERBB2, FRK | SMN1; SMN2 1644/4885ALDH1A1 2915/4885HTT 4415/4885 |
| US-20250101018-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | MAPT, APP, SLCO1B3 | SMN1; SMN2 2412/4885ALDH1A1 1918/4885HTT 10/4885 |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | ABL1, TH, CYP3A43 | SMN1; SMN2 4531/4885ALDH1A1 1008/4885HTT 531/4885 |
| US-12116364-B2 | Heteroaryl compounds and uses thereof | MAPT, APP, SLCO1B3 | SMN1; SMN2 2412/4885ALDH1A1 1918/4885HTT 10/4885 |
| US-20110098292-A1 | New Compounds Useful for Treating CNS Disorders | SLC18A2, PMP22, GAP43 | SMN1; SMN2 138/4885ALDH1A1 1045/4885HTT 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.